Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Autism rates among U.S. children is one in 91, says new report

A new report out yesterday places autism rates among U.S. children at one in 91, with autism now affecting one in 58 boys. These new numbers, from Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, are prompting outrage from parents and autism advocates over inaction from government health agencies in addressing the crisis affecting hundreds of thousands of American families.

7 Oct 2009

Swine Flu vaccine arrives as flu moves quickly through population

The first doses of Swine Flu have arrived in the United States, as health officials work quickly to inoculate people against the virus.

7 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

New cases of H1N1 worldwide up 24,000 in two weeks

The number of H1N1 (swine flu) cases reported in WHO regions worldwide has grown by at least 24,000 in two weeks to cross the 340,000 mark since the virus was first detected in mid-April, the CDC reported Monday, according to Agence France-Presse.

7 Oct 2009

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Memorial Blood Centers today outlined steps the organization is taking to stay prepared for the spread of the H1N1 virus and to ensure a safe experience for blood donors and an ample blood supply for our communities.

7 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

Majority of Europeans not concerned about H1N1

Three quarters of European people surveyed between the 30th April and 6th May 2009 said they were either not at all concerned or only a little concerned about swine flu.

6 Oct 2009

U.N. officials highlight need for vaccine assistance to poor countries

U.N. officials on Sunday said that the H1N1 (swine flu) virus had arrived in poorer countries, highlighting a growing need for financial assistance and H1N1 vaccines for such regions, SAPA/News24.com reports.

6 Oct 2009

Research reveals that 52% Americans are not worried about H1N1 virus and its impact

As the first recipients of the H1N1 vaccine are vaccinated, more than half of Americans surveyed (52 percent) do not believe the H1N1 virus, or Swine Flu, will have a major impact in the United States compared to 44 percent who believe it will, according to the results of a new Deloitte Center for Health Solutions survey.

6 Oct 2009

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Theraclone Sciences, Inc., a Seattle-based biotechnology company, and Zenyaku Kogyo Co., Ltd., a pharmaceutical company based in Tokyo, today announced that they have entered into a multi-year research and development agreement.

5 Oct 2009

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus (SynConTM) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets.

5 Oct 2009

Misuse of aspirin might have caused high death rate during 1918-1919 influenza pandemic

The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Appearing in the November 1 issue of Clinical Infectious Diseases and available online now, the article sounds a cautionary note as present day concerns about the novel H1N1 virus run high.

3 Oct 2009

Surgical masks nearly as effective as N95 respirators in protecting health care workers against influenza

Surgical masks appear to be no worse than, and nearly as effective as N95 respirators in preventing influenza in health care workers, according to a study released early online today by JAMA. The study was posted online ahead of print because of its public health implications. It will be published in the November 4 issue of JAMA.

3 Oct 2009

Surgical masks appear as effective as N95 respirators against influenza: Study

A McMaster University study has found that surgical masks appear to be as good as N95 respirators in protecting health-care workers against influenza.

3 Oct 2009

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac has received its second purchase order for its H1N1 vaccine, PANFLU.1, from the Ministry of Industry and Information Technology of the People's Republic of China for the national stockpiling plan.

3 Oct 2009

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

Face mask: A vital tool in fighting H1N1

With flu season officially underway on October 4th, Cantel Medical Corp., a company dedicated to infection prevention and control, recommends that Americans take extra precautions against spreading H1N1 influenza. Crosstex International, a subsidiary of Cantel Medical, is one of the largest U.S. manufacturers of face masks.

3 Oct 2009

Interim results of Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine clinical trials announced

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults 18 years through 64 years of age and over the age of 65 years.

3 Oct 2009

EMEA grants positive opinion for Baxter's CELVAPAN H1N1 pandemic vaccine

Baxter International Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) granted its “positive opinion” for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. This positive opinion confirms the acceptability of Baxter’s regulatory submission to obtain final marketing authorization and licensure of the product.

From Baxter International Inc. 3 Oct 2009

First U.S. patients could receive H1N1 vaccine next week

U.S. health officials announced Thursday the first batches of the H1N1 (swine flu) vaccine the government ordered will begin arriving in designated locations across the country on Tuesday and may be administered in the first patients by the end of next week, Reuters reports (Fox, 10/1).

3 Oct 2009

Pandemic News and Research

Further Reading

Autism rates among U.S. children is one in 91, says new report

Swine Flu vaccine arrives as flu moves quickly through population

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

New cases of H1N1 worldwide up 24,000 in two weeks

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Vivaldi receives US patent for live attenuated influenza vaccines

Majority of Europeans not concerned about H1N1

U.N. officials highlight need for vaccine assistance to poor countries

Research reveals that 52% Americans are not worried about H1N1 virus and its impact

Theraclone and Zenyaku Kogyo sign multi-year research and development agreement

Inovio's SynCon H1N1 achieves protective antibody response against pandemic influenza in ferrets

Misuse of aspirin might have caused high death rate during 1918-1919 influenza pandemic

Surgical masks nearly as effective as N95 respirators in protecting health care workers against influenza

Surgical masks appear as effective as N95 respirators against influenza: Study

Chinese government places second purchase order for Sinovac Biotech's H1N1 vaccine

DelSite's assests acquired by Nanotherapeutics

Face mask: A vital tool in fighting H1N1

Interim results of Sanofi Pasteur's Influenza A (H1N1) 2009 Monovalent Vaccine clinical trials announced

EMEA grants positive opinion for Baxter's CELVAPAN H1N1 pandemic vaccine

First U.S. patients could receive H1N1 vaccine next week

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News